Volume | 166 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Coherus BioSciences Inc | CHRS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.93 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
2 | 166 | - | 1.4301 - 8.22 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
05:05:11 | 66 | $ 1.94 | USD |
Coherus BioSciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
214.93M | 111.36M | - | 257.24M | -237.89M | -2.14 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Coherus BioSciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CHRS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.02 | 2.245 | 1.91 | 2.06 | 1,658,017 | -0.07 | -3.47% |
1 Month | 2.40 | 2.61 | 1.91 | 2.25 | 1,736,152 | -0.45 | -18.75% |
3 Months | 2.03 | 2.87 | 1.91 | 2.35 | 2,579,496 | -0.08 | -3.94% |
6 Months | 2.90 | 3.73 | 1.4301 | 2.50 | 5,044,508 | -0.95 | -32.76% |
1 Year | 7.80 | 8.22 | 1.4301 | 3.30 | 4,062,533 | -5.85 | -75.00% |
3 Years | 14.90 | 19.32 | 1.4301 | 5.65 | 1,972,283 | -12.95 | -86.91% |
5 Years | 14.95 | 23.91 | 1.4301 | 9.12 | 1,638,126 | -13.00 | -86.96% |
Coherus BioSciences Description
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States. |